Table 1 Baseline characteristics

Age (years)

62 (45–67)

52 (39–62)

64 (57–67)

0.12

Female

8 (53)

5 (71)

3 (38)

0.32

Systolic BP (mmHg)

140 (124–148)

124 (114–140)

147 (135–164)

0.037

Diastolic BP (mmHg)

82 (72–86)

80 (67–86)

83 (79–89)

0.29

Serum Creatinine (mg/dL)

1.2 (0.8–1.5)

0.8 (0.5–0.9)

1.3 (1.2–2.1)

0.011

eGFR (ml/min/1.73 m²)

65 (40–100)

100 (62–123)

56 (29–66)

0.024

eGFR Group

0.45

  > 60 ml/min/1.73 m²

10 (67)

6 (86)

4 (50)

 30–60 ml/min/1.73 m²

3 (20)

1 (14)

2 (25)

  < 30 ml/min/1.73 m²

2 (13)

0 (0)

2 (25)

UPCR (g/g)

8.2 (6.8–11.4)

6.9 (5.2–10.2)

10.1 (8.0–11.7)

0.15

UPCR group

0.41

  < 4^a

1 (7)

1 (14)

0 (0)

 4–8

5 (33)

3 (43)

2 (25)

  > 8

9 (60)

3 (43)

6 (75)

Nephrotic Syndrome^b

13 (87)

7 (100)

6 (75)

0.47

Albumin (g/dL)

2.7 (2.5–2.8)

2.7 (2.5–2.8)

2.6 (2.4–3.1)

0.86

Total Cholesterol (mg/dL)^c

350 (252–371)

341 (252–367)

371 (249–438)

0.34

Triglycerides (mg/dL)^c

172 (122–270)

134 (77–192)

177 (155–546)

0.14

Time Since Biopsy Diagnosis (months)

9 (3–24)

3 (0.5–4)

23 (16–60)

0.011

On ACE-I or ARB

13 (87)

5 (71)

8 (100)

0.20

On Statin

8 (53)

2 (29)

6 (75)

0.13

Treatment Indications

 Failure of ACE-I or ARB^d

8 (53)

2 (29)

6 (75)

0.13

 Declining Renal Function

5 (33)

1 (14)

4 (50)

0.30

 Debilitating Symptoms from nephrotic syndrome

10 (67)

5 (71)

5 (63)

0.99

 Relapsing Disease

6 (38)

NA

6 (75)

NA

 Refractory Disease

3 (19)

NA

3 (38)

NA